Compare Amphastar Pharmaceuticals Inc (AMPH) vs British American Tobacco PLC (BTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs British American Tobacco PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.72 (market cap $868.62M), while British American Tobacco PLC trades at $56.24 (market cap $122.36B). The key difference: British American Tobacco PLC is far larger — about 140.9× Amphastar Pharmaceuticals Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BTI | |
|---|---|---|
Market Cap | $868.62M | $122.36B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $66.70 |
52-Week Low | $16.87 | $50.39 |
Enterprise Value | $1.27B | $166.31B |
Dividend Yield | — | 5.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
BTI trades at $57.05, down 3.84% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 24.99% net income margin and 13.33% ROE. Recent earnings show three beats out of four quarters, while cash flow turned negative in 2025. The company is pivoting to next-generation nicotine products like Velo, supported by a multi-year tech partnership with ITC Infotech announced in August 2026.
The outlook is mixed: valuation appears reasonable with a P/E of 14.48, and analyst consensus is 66.7% buy ratings, but technical indicators are bearish and regulatory risks persist. The stock offers income potential with dividends, yet faces headwinds from declining combustibles and recent workforce cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
